Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers. Early changes in circulating tumor DNA (ctDNA) level may provide early response prediction, but the impact of tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Leary, Ben, Hrebien, Sarah, Morden, James P., Beaney, Matthew, Fribbens, Charlotte, Huang, Xin, Liu, Yuan, Bartlett, Cynthia Huang, Koehler, Maria, Cristofanilli, Massimo, Garcia-Murillas, Isaac, Bliss, Judith M., Turner, Nicholas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832789/
https://www.ncbi.nlm.nih.gov/pubmed/29497091
http://dx.doi.org/10.1038/s41467-018-03215-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832789/
https://www.ncbi.nlm.nih.gov/pubmed/29497091
http://dx.doi.org/10.1038/s41467-018-03215-x

Ejemplares similares